As if BMS didn’t have enough to worry about, what with major investors trying to scuttle its $74 billion Celgene buy, now a new concern has emerged—and it involves one of the six candidates BMS executives have cited as justification
read moreEli Lilly CEO David Ricks, in his second year on the job, snared a larger pay package than those of a few of his Big Pharma peers. And it’s not far shy of the amount his predecessor, John Lechleiter, hauled
read moreA few years ago India’s Alkem Laboratories was in the hot seat with the FDA, having had several plants cited by inspectors. Today it is in the driver’s seat after the agency approved its new valsartan offering to help relieve
read moreThe Department of Health and Human Services confirmed that Ned Sharpless, currently the director of the National Cancer Institute, will serve as acting FDA chief. More: HHS confirms Sharpless to serve as acting FDA chief Source: fierce
read moreJohnson & Johnson’s Darzalex is already on track to nab a second multiple myeloma nod in newly diagnosed patients in the U.S., but its journey with England’s cost watchdog hasn’t been so smooth. More: NICE limits coverage of Johnson & Johnson, Takeda’s
read moreThe plant in India where Biocon makes the biosimilars it shares with Mylan was given a clean bill of health by the FDA last year—but not for long. The FDA posted a new Form 483 for the facility Tuesday following
read more© 1994 - 2026 B.M. Pharmaceuticals